Primary Immunodeficiency Disease: A Physician’s Perspective
Dr. Terry Harville, a leading expert in the treatment of primary immunodeficiency diseases, was involved in the early stages of treatment options.
Beating the Odds with CVID
A diagnosis of primary immunodeficiency (PI) often leads to varying degrees of disability. For Brandon Dillon, it offered an opportunity to find untapped reserves of resilience.
Leveraging the Benefits of Biologic Medicines
With the growing demand for biologics, biosimilars promise additional treatment options, but their introduction is not without challenges.
Infusing Hope: Living with Hemophilia
Advances in treatment of this long-misunderstood disease allow patients like Daniel Kraus to lead normal, active lives.
Advancing Healthcare: From Testing to Treatment
On average, only 25 new experimental drugs were approved by the FDA’s Center for Drug Evaluation and Research (CDER) every year during the past decade. Taking more than 10 years to go from testing to treatment, the healing properties of these drugs help countless numbers of patients, sometimes providing life-changing and lifesaving results.
Addressing Declining Vaccination Rates
A “vaccination gap” has resulted in fewer children receiving the recommended immunizations, and diseases that were once considered all but eliminated are reemerging.
Measles: A Patient’s Perspective
This California family thought a trip to Disneyland would be the perfect way to celebrate their new baby. Unfortunately, the Loops came home with much more than the happy memories they had hoped for.
Sleep Disorders: A Patient’s Perspective
Narcolepsy is often misdiagnosed and frequently misunderstood. Most individuals experience symptoms for an average of three to five years before receiving an accurate diagnosis, although 10- to 15-year delays are not uncommon.
Sleep Disorders: A Physician’s Perspective
Dr. Peter A. Fotinakes has made it his life’s commitment to treat sleep apnea, which is his passion.
Safe Medicine: A Shared Responsibility
FFF Enterprises takes a “safety first” approach when it comes to business best practices for distributing fragile biologics and transport-sensitive vaccines.